Showing 3961-3970 of 4165 results for "".
- SIFI Completes Enrollment of the Phase 3 Study of Polihexanide 0.08% for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-completes-enrollment-of-the-phase-3-study-of-polihexanide-0-08-for-the-treatment-of-acanthamoeba-keratitis/2478575/SIFI announced that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pivotal phase 3 clinical trial (043/SI). The full enrollment in the trial is an important milestone in addressing the unmet need for treating AK infections. It also paves the way
- Adverum Biotechnologies Announces Positive Interim Data From OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2478553/Adverum Biotechnologies announced positive new interim data from Cohorts 1-4 of the OPTIC phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). “With these impre
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Neurotech Pharmaceuticals Appoints John Pollack, MD, as Chief Medical Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-john-pollack-md-as-chief-medical-officer/2478549/Neurotech Pharmaceuticals announced that John Pollack, MD, has been appointed to the position of Chief Medical Officer (CMO). Dr. Pollack’s responsibilities will include the execution of clinical studies, patient safety, and the management of Medical Affairs; supporting the required regulatory su
- Wize Pharma Announces Positive Topline Results in Phase 4 Study of LO2A for Dry Eye in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-positive-topline-results-in-phase-4-study-of-lo2a-for-dry-eye-in-patients-with-sjogrens-syndrome/2478529/Wize Pharma reported topline results from its phase 4 clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome. The randomized, double-masked comparative study evaluated LO2A versus Alcon̵
- Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpointhttps://modernod.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/Aurinia Pharmaceuticals announced topline data from the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10 mm or greater improvem
- RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trialhttps://modernod.com/news/regenerx-joint-venture-enrolls-last-subject-in-phase-3-dry-eye-trial/2478468/RegeneRx Biopharmaceuticals announced that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome. Completion of treatment and follow-up for the last subject is anticipated to be by the end of Novem
- Allergan Announces Positive Phase 3 Topline Results for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478467/Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1,
- iVeena Announces Positive Topline Results of IVMED-80 Eye Drops for Keratoconushttps://modernod.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/iVeena has announced topline results of its recently completed phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6- or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) coul
- Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trialhttps://modernod.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-mont-blanc-phase-3-trial/2478456/Nicox SA announced that its partner, Ocumension Therapeutics, has received approval from China’s Center for Drug Evaluation of the National Medical Products Administration to carry out the Chinese part of the ongoing Mont Blanc trial, the first phase 3 clinical trial on NCX 470 for the lowering o